Literature DB >> 25339736

Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke.

Fang Wu1, Marcela Catano1, Ramiro Echeverry1, Enrique Torre1, Woldeab B Haile1, Jie An2, Changhua Chen1, Lihong Cheng1, Andrew Nicholson3, Frank C Tong4, Jaekeun Park5, Manuel Yepes6.   

Abstract

Spines are dendritic protrusions that receive most of the excitatory input in the brain. Early after the onset of cerebral ischemia dendritic spines in the peri-infarct cortex are replaced by areas of focal swelling, and their re-emergence from these varicosities is associated with neurological recovery after acute ischemic stroke (AIS). Urokinase-type plasminogen activator (uPA) is a serine proteinase that plays a central role in tissue remodeling via binding to the urokinase plasminogen activator receptor (uPAR). We report that cerebral cortical neurons release uPA during the recovery phase from ischemic stroke in vivo or hypoxia in vitro. Although uPA does not have an effect on ischemia- or hypoxia-induced neuronal death, genetic deficiency of uPA (uPA(-/-)) or uPAR (uPAR(-/-)) abrogates functional recovery after AIS. Treatment with recombinant uPA after ischemic stroke induces neurological recovery in wild-type and uPA(-/-) but not in uPAR(-/-) mice. Diffusion tensor imaging studies indicate that uPA(-/-) mice have increased water diffusivity and decreased anisotropy associated with impaired dendritic spine recovery and decreased length of distal neurites in the peri-infarct cortex. We found that the excitotoxic injury induces the clustering of uPAR in dendritic varicosities, and that the binding of uPA to uPAR promotes the reorganization of the actin cytoskeleton and re-emergence of dendritic filopodia from uPAR-enriched varicosities. This effect is independent of uPA's proteolytic properties and instead is mediated by Rac-regulated profilin expression and cofilin phosphorylation. Our data indicate that binding of uPA to uPAR promotes dendritic spine recovery and improves functional outcome following AIS.
Copyright © 2014 the authors 0270-6474/14/3414219-14$15.00/0.

Entities:  

Keywords:  cerebral ischemia; recovery; stroke; urokinase-type plasminogen activator

Mesh:

Substances:

Year:  2014        PMID: 25339736      PMCID: PMC4205548          DOI: 10.1523/JNEUROSCI.5309-13.2014

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  62 in total

1.  Carbocyanine dyes. Novel markers for labelling neurons.

Authors:  M G Honig; R I Hume
Journal:  Trends Neurosci       Date:  1989-09       Impact factor: 13.837

2.  A semiautomated method for measuring brain infarct volume.

Authors:  R A Swanson; M T Morton; G Tsao-Wu; R A Savalos; C Davidson; F R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  1990-03       Impact factor: 6.200

3.  Functional recovery of forelimb response capacity after forelimb primary motor cortex damage in the rat is due to the reorganization of adjacent areas of cortex.

Authors:  M A Castro-Alamancos; J Borrel
Journal:  Neuroscience       Date:  1995-10       Impact factor: 3.590

4.  Localization of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse forebrain during postnatal development.

Authors:  M R Del Bigio; S Hosain; M Altumbabic
Journal:  Int J Dev Neurosci       Date:  1999-07       Impact factor: 2.457

5.  Urokinase anchors uPAR to the actin cytoskeleton.

Authors:  Audrey M Bernstein; Roseanne S Greenberg; Lavinia Taliana; Sandra K Masur
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-09       Impact factor: 4.799

6.  Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis.

Authors:  H Benveniste; J Drejer; A Schousboe; N H Diemer
Journal:  J Neurochem       Date:  1984-11       Impact factor: 5.372

7.  Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.

Authors:  N Nagai; M De Mol; H R Lijnen; P Carmeliet; D Collen
Journal:  Circulation       Date:  1999-05-11       Impact factor: 29.690

8.  Urokinase-type plasminogen activator expression by neurons and oligodendrocytes during process outgrowth in developing rat brain.

Authors:  M A Dent; Y Sumi; R J Morris; P J Seeley
Journal:  Eur J Neurosci       Date:  1993-06-01       Impact factor: 3.386

9.  Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.

Authors:  Manuel Yepes; Maria Sandkvist; Elizabeth G Moore; Thomas H Bugge; Dudley K Strickland; Daniel A Lawrence
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 10.  Dil and diO: versatile fluorescent dyes for neuronal labelling and pathway tracing.

Authors:  M G Honig; R I Hume
Journal:  Trends Neurosci       Date:  1989-09       Impact factor: 13.837

View more
  20 in total

Review 1.  Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke.

Authors:  Rais Reskiawan A Kadir; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2019-09-24       Impact factor: 5.046

2.  Urokinase-type Plasminogen Activator (uPA) Binding to the uPA Receptor (uPAR) Promotes Axonal Regeneration in the Central Nervous System.

Authors:  Paola Merino; Ariel Diaz; Valerie Jeanneret; Fang Wu; Enrique Torre; Lihong Cheng; Manuel Yepes
Journal:  J Biol Chem       Date:  2016-12-16       Impact factor: 5.157

3.  Urokinase-type plasminogen activator (uPA) regulates the expression and function of growth-associated protein 43 (GAP-43) in the synapse.

Authors:  Paola Merino; Ariel Diaz; Enrique R Torre; Manuel Yepes
Journal:  J Biol Chem       Date:  2019-12-09       Impact factor: 5.157

4.  A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.

Authors:  Ariel Diaz; Paola Merino; Luis Guillermo Manrique; Juan Pablo Ospina; Lihong Cheng; Fang Wu; Valerie Jeanneret; Manuel Yepes
Journal:  J Neurosci       Date:  2017-09-20       Impact factor: 6.167

5.  Urokinase-type plasminogen activator (uPA) promotes ezrin-mediated reorganization of the synaptic cytoskeleton in the ischemic brain.

Authors:  Paola Merino; Ariel Diaz; Luis Guillermo Manrique; Lihong Cheng; Manuel Yepes
Journal:  J Biol Chem       Date:  2018-05-02       Impact factor: 5.157

6.  Tissue-type plasminogen activator protects the postsynaptic density in the ischemic brain.

Authors:  Valerie Jeanneret; Juan P Ospina; Ariel Diaz; Luis G Manrique; Paola Merino; Laura Gutierrez; Enrique Torre; Fang Wu; Lihong Cheng; Manuel Yepes
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-16       Impact factor: 6.200

7.  Urokinase-type plasminogen activator (uPA) protects the tripartite synapse in the ischemic brain via ezrin-mediated formation of peripheral astrocytic processes.

Authors:  Ariel Diaz; Paola Merino; Luis G Manrique; Lihong Cheng; Manuel Yepes
Journal:  J Cereb Blood Flow Metab       Date:  2018-06-12       Impact factor: 6.200

8.  Brain ischemic insult induces cofilin rod formation leading to synaptic dysfunction in neurons.

Authors:  Liang Shu; Ben Chen; Bin Chen; Hai Xu; Guoxiang Wang; Yian Huang; Yingya Zhao; Hui Gong; Min Jiang; Lidian Chen; Xu Liu; Yun Wang
Journal:  J Cereb Blood Flow Metab       Date:  2018-06-22       Impact factor: 6.200

9.  The Plasminogen Activation System Promotes Dendritic Spine Recovery and Improvement in Neurological Function After an Ischemic Stroke.

Authors:  Valerie Jeanneret; Manuel Yepes
Journal:  Transl Stroke Res       Date:  2016-02-04       Impact factor: 6.829

10.  Urokinase-type plasminogen activator promotes N-cadherin-mediated synaptic recovery in the ischemic brain.

Authors:  Ariel Diaz; Paola Merino; Patrick McCann; Manuel A Yepes; Laura G Quiceno; Enrique Torre; Amelia Tomkins; Xiaodong Zhang; Chadwick M Hales; Frank C Tong; Manuel Yepes
Journal:  J Cereb Blood Flow Metab       Date:  2021-03-24       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.